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Abstract
Background: Qualitative and quantitative changes in IGRA response offer promise as biomarkers to monitor Tuberculosis
(TB) drug therapy, and for the comparison of new interventions. We studied the decay kinetics of TB-specific antigen T-cell
responses measured with an in-house ELISPOT assay during the course of therapy.
Methods: Newly diagnosed sputum smear positive TB cases with typical TB chest radiographs were recruited. All patients
were given standard anti-TB treatment. Each subject was followed up for 6 months and treatment outcomes were
documented. Blood samples were obtained for the ESAT-6 and CFP-10 (EC) ELISPOT at diagnosis, 1-, 2-, 4- and 6-months.
Qualitative and quantitative reversion of the ELISPOT results were assessed with McNemar test, conditional logistic
regression and mixed-effects hierarchical Poisson models.
Results: A total of 116 cases were recruited and EC ELISPOT was positive for 87% (95 of 109) at recruitment. There was a
significant decrease in the proportion of EC ELISPOT positive cases over the treatment period (p,0.001). Most of the
reversion occurred between the start and first month of treatment and at completion at 6 months. ESAT-6 had higher
median counts compared to CFP-10 at all time points. Counts for each antigen declined significantly with therapy
(p,0.001). Reverters had lower median SFUs at the start of treatment compared to non-Reverters for both antigens. Apart
from the higher median counts for non-Reverters, no other risk factors for non-reversion were found.
Conclusions: TB treatment induces qualitative and quantitative reversion of a positive in-house IGRA in newly diagnosed
cases of active TB disease. As this does not occur reliably in the majority of cured individuals, qualitative and quantitative
reversion of an IGRA ELISPOT has limited clinical utility as a surrogate marker of treatment efficacy.
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Introduction
Tuberculosis (TB) is responsible for the greatest number of
deaths attributable to a single infectious agent worldwide and most
of this mortality is in developing countries.[1] New diagnostic
tools, and enhanced treatment strategies, are needed to help
combat the TB epidemic. These need to be shown to be useful in
TB-endemic tropical settings. Interferon gamma release assays
(IGRAs) are utilised in the diagnosis of latent tuberculosis infection
(LTBI).[2,3] However, their performance appears to vary between
high burden, resource limited settings and low burden coun-
tries.[4] They may also have value in the evaluation of new tools
against TB.
The magnitude of the Mycobacterium (M.) tuberculosis antigen-
specific interferon gamma (IFN-g) T-cell response to infecting M.
tuberculosis is hypothesized to be proportional to the antigenic load
of the infecting organism in human and animal models.[5,6] We
have shown that the quantitative response, as measured by
ELISPOT, correlates with exposure to a TB case, reflecting the
infectious load of M. tuberculosis. Sharply rising counts following
exposure may be predictive of TB disease.[7,8] Effective treatment
for LTBI is associated with a decrease in the measured response to
ESAT-6 and CFP-10 antigens.[9,10] Studies have also shown
significant qualitative and quantitative reversion of the response
following treatment of adult and paediatric TB cases in different
settings.[11,12,13]
Qualitative and quantitative changes in IGRA response offer
promise as biomarkers to monitor the response to TB drug
therapy, and for the comparison of new interventions. However,
more needs to be known about the nature of the changes in the
IGRA response. Having determined that, even in a TB-endemic
tropical setting, ELISPOT counts decrease significantly in TB
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12502cases after treatment[14], we studied the decay kinetics of TB-
specific antigen T-cell responses during the course of treatment.
Methods
Participants
Newly diagnosed TB cases at the Medical Research Council
(MRC) out-patient clinic and the major government TB chest
clinic were consecutively recruited to the study. They were eligible
if they were $15 years old, were sputum smear positive and had a
typical TB chest x-ray. Blood samples were obtained for full blood
count, HIV testing and EC ELISPOT at recruitment. In addition,
follow-up samples were collected at 1-, 2-, 4- and 6-months of
treatment. All patients received standard anti-tuberculosis treat-
ment provided free by the Gambian National TB Control
Programme. Patients’ clinical outcomes were reviewed at each
follow-up visit and their treatment cards checked for compliance/
adherence to treatment. Treatment outcomes were documented as
cured, completed treatment, defaulted, treatment failure, trans-
ferred out and died according to standard World Health
Organization (WHO) definitions.[15] Each subject was followed
for total period of 6 months. At the end of the follow-up period we
documented if the patient was alive/dead, the presence of clinical
symptoms suggestive of TB (chronic cough, weight loss, night
sweats, etc), a new diagnosis of TB, ongoing re-treatment or
treatment for mono- or multi-drug resistant TB.
Ethics Statement
The joint MRC-Gambian Government Ethics committee gave
ethical approval for this study. Written informed consent was
obtained from all enrolled study participants.
Laboratory Procedures
Sputum smear microscopy was done on samples stained with
auramine phenol and Ziehl-Neelsen. Isolation and identification of
M. tuberculosis was as previously described using Lowenstein-Jensen
medium and BACTEC 9000 liquid media.[16] HIV status was
determined by enzyme linked immunosorbent assays (Murex
1.2.0, Abbott-Murex Biotec, Dartford, Kent, UK), Hexagon HIV
(Human Diagnostics GmbH, Wiesbaden, Germany) and type
specific immunoblotting kit (Pepti-LAV I/II, BIORAD, Marnes-
la-Coquette, France) for confirmation.
The ex-vivo ELISPOT assays for IFN-c were performed as
previously described.[17,18] The antigens used in this study were
15 amino acids long synthetic, sequential peptides spanning the
length of ESAT-6 and CFP-10 (ABC, Imperial College, London,
UK). Each peptide overlapped its adjacent peptide by 10 residues.
ESAT-6 and CFP-10 peptide pools were used at 5mg/ml while
Phytohaemaglutinin (PHA 5 mg/ml; Sigma, Aldrich, UK) was
used as positive control with medium as negative control.
Peripheral blood mononuclear cell (PBMCs) separation and
fresh ex vivo ELISPOT were done within 4 hours of sampling by
laboratory staff blind to clinical information: 200,000 PBMCs, per
well were incubated with all antigens and tested in duplicate wells.
Spot forming units (SFUs) were counted with an automated
ELISPOT reader (AID-GmbH, Strasberg, Germany). Positive test
wells were pre-defined as containing at least 8 SFUs/well/2610
5
PBMCs more than negative control wells.[19] For a positive
ESAT-6/CFP-10 result it was necessary for one or more pools of
overlapping peptides to be positive. PHA wells were set to at least
150 SFUs/well/2610
5 PBMCs above negative control wells.
Negative control wells were required to have less than 20 SFUs/
well/2610
5 PBMCs.[19] The ELISPOT was considered to have
failed if the specifications for the negative control and PHA wells
were not met. With respect to reproducibility, we have previously
shown that within-subject variability of our ELISPOT assay is very
small compared to between-subject variability.[14]
Data management and analysis
All data were double entered into an Access relational database.
Statistical analyses were performed using Stata 11.1 (Stata Corp
LP, College Station, Texas). The main outcomes of interest were
qualitative and quantitative reversion of the EC ELISPOT during
the period TB treatment. The impact of HIV status, age, sputum
smear grade and findings on chest radiographs on reversion was
also evaluated. McNemar tests were used to assess the relationship
between qualitative CFP-10, ESAT-6, final EC ELISPOT and
time points at testing. Conditional logistic regression was used to
test for trend across time points. Quantitative reversion was
assessed by Wilcoxon signed-rank test and mixed-effect hierarchi-
cal Poisson models adjusting for possible confounding factors, such
as age, gender, HIV status, BCG scar, sputum smear grade and
severity of radiologic disease. A p-value ,0.05 was considered
significant.
Results
Study population
One hundred and sixteen smear positive TB cases were eligible;
113 (97%,) were culture positive. The median age was 27.5 years
(minimum: 15 years, maximum: 71 years), there were 3 times
more males than females and less than 10% were HIV infected
(Table 1). Ninety-six (82.8%) cases completed treatment in 6
months, 4 (3.4%) defaulted, 1(0.9%) died, 11(9.5%) transferred out
and for 4 (3.4%) treatment outcome could not be determined.
There were 112 with 2 or more EC ELISPOT results and 86 with
3 or more results.
Qualitative results over time
At recruitment, 95 of 109 cases (87.2%; 95% confidence
interval (95% CI): 79.4–92.8%) with valid results had a positive
EC ELISPOT. As seen in Figure 1, there was a significant change
in the proportion EC ELISPOT positive over the time of
treatment (coefficient (coeff): 20.38, 95% CI: 20.54 to 20.22,
p,0.001). Most of the qualitative reversion seen occurred between
recruitment and first month of therapy (87.2% vs. 70.0% (95% CI:
56.8–81.2%) positive, p,0.001, McNemar’s test) and at comple-
tion of treatment at 6 months (87.2% vs. 54.3% (95% CI: 41.9–
66.3%) positive p,0.001, McNemar’s test).
Four (4.7%) cases did not achieve sputum conversion to
negative at 2 months. Their EC ELISPOT remained positive for
the entire course of therapy, although they were declared cured by
completion of the standard treatment regimen. Of the cases with
ELISPOT results at 6 months, only 1 (14.3%) out of 7 with
negative results at recruitment had conversion to a positive result.
This subject’s sputum had the maximum smear grade at diagnosis,
the TB affected 3 lung zones and was one of those for whom
treatment outcome could not be determined.
ESAT-6. There were 85 cases (73.3%; 95% CI: 65.1–81.4%)
with positive ESAT-6 results. Following 1 and 6 months of
treatment, 49.2% (95%CI: 36.5–61.9%) and 41.0% (95%CI:
29.9–52.2) remained positive respectively. Overall, there was 24%
reversion at 1-month and 33% reversion at 6-months. The change
in proportion of positive ESAT-6 results decreased significantly
from recruitment to the end of the first month of treatment
(p=0.028, McNemar test) and between recruitment and 6 months
of therapy (p,0.001, McNemar test). Overall the positivity rate
changed significantly with duration of treatment (coeff: 20.35,
IGRA Reversion with TB Therapy
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with a negative result at recruitment for whom 6-month results
were available (78) became positive. This subject had a sputum
smear grade of 2+, 3 lung zones affected by disease without cavities
on chest radiograph and was declared cured at the end of TB
therapy.
CFP-10. There were 70 cases (62.0%; 95% CI: 52.3–70.9%)
positiveforCFP-10at recruitment. This declinedto 44.4%(95%CI:
31.9–57.1%) after one month of anti-tuberculosis treatment and to
32.1% (95%CI: 21.5–42.6%) after 6 months of treatment. The
reversion of test results at the 1
st and 6
th months of therapy
compared to baseline were statistically significant (p=0.023 and
p,0.001 at 1 and 6 months, respectively). Across follow-up periods
and with treatment, the change in positivity was also significant
(coeff.: 20.23, 95% CI: 20.35 to 20.12, p,0.001). CFP-10 results
were available at 6 months for 78 cases. Five (16.8%) of those with
negative results at recruitment (30) became CFP-10 positive after
completion of TB therapy. All 5 had the maximum smear grade on
sputum microscopy at diagnosis, 3–4 lung zones affected by TB and
4 of 5 were cured at 6 months. The other did not have adequate
treatment outcome data.
The difference in proportions of reverters for both antigens was
not significant (ESAT-6: 28/71 (58.3%), CFP-10: 28/85 (47.5%),
p=0.26).
Quantitative results with treatment over time
ESAT-6. The median decline in SFUs was 1.7 and 5.5-fold
from recruitment to the end of the 1
st and 6
th month of treatment,
respectively (Figure 2). The median SFUs at the start of treatment
was 20.8 [interquartile range (IQR): 8.5–57.8], dropping to
8.5 [IQR 2.0–25.0] at 1-month and 4.5 [IQR 0.5–19.0] on
completion of treatment. Similar to the qualitative results, ESAT-6
SFUs showed a 2-step decline in SFUs within the first month of
therapy (p=0.06) and between the 1st and 6
th month of treatment
(p,0.001). Overall, there was a significant decline in SFUs over
time with increasing duration of treatment (p,0.0001). The effect
of treatment and time on ESAT-6 SFUs remained significant after
adjusting for age, gender, ethnicity, HIV status, BCG scar status,
sputum grade, and severity of radiologic disease.
CFP-10. Median values of CFP-10 were significantly lower
than those for ESAT-6 SFUs at diagnosis (p=0.002) and all other
time points but after the 1st month of treatment (p=0.16,
p=0.029, p=0.006, and 0.06, respectively). There was a 2-fold
median decline in CFP-10 SFUs between recruitment and the first
month of treatment increasing to a 4.5-fold median decline
between recruitment and 6th months of treatment. The declines in
median SFUs between recruitment (13.5, [IQR 4.5–34.3]) and 1-
month (7.0, [IQR 3.0–17.5]) and between recruitment and 6-
months, were statistically significant (p=0.03 and p,0.001
respectively). Overall, there was a significant decline in SFUs
over time with increasing duration of treatment (p,0.001). This
was unaffected by sputum grade, gender, severity of radiologic
disease, BCG scar status and ethnicity.
Quantitative ELISPOT results in Reverters compared to
non-Reverters
A group of cases with positive results at onset of treatment and
negative results after 6 months of therapy i.e. Reverters were
compared to non-Reverters. For ESAT-6, there was approxi-
mately a median 15.2-fold change in SFUs from start of to
completion of treatment for Reverters and a 2-fold change for
non-Reverters. Similarly, there was a 17.4- and 3.3-fold change for
CFP-10 for the 2 groups respectively over the same periods. As
shown in Figure 3A and 3B, the median ESAT-6 in Reverters at
the start and end of treatment was 19.5 [IQR 8.5–36.0] SFUs and
1.5 [IQR 0.0–3.5] SFUs compared to 44 [IQR 19.0–120.0] SFUs
and 19.0 [IQR 11.5–54.5] SFUs respectively in non-Reverters.
For CFP-10, median SFUs at the start and completion of
treatment were 13.0 [IQR 4.5–24.0] SFUs and 0.5 [IQR 0.0–
Figure 1. Changes in proportions of tuberculosis cases positive
for combined and individual antigen ELISPOT assay during TB
treatment and follow-up.
doi:10.1371/journal.pone.0012502.g001
Table 1. Clinical and demographic characteristics of study
population.
Characteristic All cases (n=116)
Age, years
Median (IQR) 27.5 (22–36)
Sex
Female 31 (26.7)
Male 85 (73.3)
Ethnic group
Mandinka 46 (39.7)
Jola 27 (23.3)
Wolof 14 (12.1)
Fula 7 (6.0)
Others 22 (19.0)
Sputum smear grade
Low 2 (1.7)
Medium 25 (21.6)
High 89 (76.7)
BCG scar
Present 39 (33.6)
Absent 61 (52.6)
Unknown 16 (13.8)
HIV status
Positive 10 (8.6)
Negative 101 (87.1)
Unknown 5 (4.3)
doi:10.1371/journal.pone.0012502.t001
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68.5] and SFUs 14.5 [IQR 6.5–34.0] for non-Reverters. Apart
from these higher median counts at onset of treatment, no other
risk factors for non-reversion were found. For ESAT-6, 28 of 59
(47.5%) reverted on completion of therapy compared to 58.3% (28
of 48) for CFP-10. However, the difference in proportions of
Reverters for both antigens was not significant (p=0.26).
For ESAT-6 and CFP-10, 15 and 21 cases respectively
experienced reversion and then at least one conversion. No risk
factors for this phenomenon were identified and the SFUs at start
of treatment, during the reversion and conversion episodes were
not closer to the cut-off for positive results than other episodes.
Discussion
This study describes the decay kinetics of an in-house TB
specific ELISPOT test with antituberculosis treatment in newly
diagnosed TB cases in a high burden setting. We found
approximately 17.2% of cases had qualitative reversion within
the 1st month of treatment with an increase to 32.9% by 6 months.
Our data show a 2-step decline in qualitative and quantitative test
results: the 1st and 6th month of follow-up showed the most
significant change in ELISPOT count. Comparison of quantitative
responses between reverters and non-reverters showed that non-
reverters started at a much higher level, with some differences seen
according to the antigen assessed. These results provide a
complete picture of ELISPOT decay kinetics in TB cases and
provide insights into the usefulness of the readout as a Biomarker
in TB research and practice.
The only factor associated with non-reversion was the presence
of higher SFUs for each antigen at baseline and throughout the
treatment follow-up period. Interestingly, the decline in median
SFUs for both antigens were similar for the reverter and non-
reverter groups. It appears that there is a threshold for the amount
of decline possible in the number of sensitised effector cells (SFUs)
per unit time with treatment, depending on the initial result.
Interestingly, when compared to contacts in the community using
the same test, the median SFUs for reverters decline with
treatment to values below those seen in healthy, but latently
infected TB contacts. [17,20]
Our findings of qualitative and quantitative reversion of the EC
ELISPOT test are in agreement with our data previously reported
by us and other authors for both commercial and in-house
IGRAs.[12,13,14,21–26] The 2-step reversion we found had been
previously described for contacts and cases given antituberculosis
drugs as part of regimens for prophylaxis and treatment in other
settings.[9] Reports of initial increases in median antigen SFUs
following treatment before a decline over period of therapy are not
supported by our study.[27,28] Neither do our data support a
report of an increase in median CFP-10 SFUs following
completion of treatment after an initial 3-fold decline.[23]
Higher median ESAT-6 SFUs than those of CFP-10 found here
is consistent with similar findings in TB disease and latent TB
infection in The Gambia.[17] That the reversion followed the
same pattern across time points is comparable to findings reported
by others. [24,29] Dominguez et al, found higher median SFUs for
CFP-10 at the start of and throughout the treatment period in
their study compared to ESAT-6. [23] Also reversion just for CFP-
10 and not with ESAT-6 has been reported following treatment in
latent M. tuberculosis infection.[10,30] The presence of a significant
minority of individuals with EC-ELISPOT conversion after an
initial reversion has also been reported by others.[22,23,25]
EC-ELISPOT measures the frequencies of effector T-cells
sensitised to ESAT-6 and CFP-10 antigens. These cells are
thought to closely correlate with antigen load, driven by the
burden of M.tuberculosis.[5,6,31,32] Therefore it is not surprising
that we found significant qualitative and quantitative test reversion
with effective therapy. However, 54.3% of our cases remained EC-
ELISPOT positive after TB treatment. The short incubation times
for the ELISPOT test are aimed at measurement of interferon
gamma produced by short lived effector T-cells. However, it is
possible that some memory T-cells come into play despite the
short incubation period. Furthermore, it has been shown that in
some people effector cells continue to circulate in the absence of
antigen.[33] Persistent T-cell responses despite clinical and
bacteriologically confirmed resolution of active TB or latent TB
Figure 2. Comparison of median SFUs across time points for ESAT-6 and CFP-10. Error bars represent the interquartile range (IQR).
doi:10.1371/journal.pone.0012502.g002
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doi:10.1371/journal.pone.0012502.g003
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components.[10,13,22,34,35] An alternative explanation is that
the mycobacterial burden is simply reduced by effective therapy,
rather than eliminated. This may be the case as there is evidence
of recurrence of TB of the same molecular fingerprint in treated
cases.[36,37]
The immediate consequence of the ‘high proportion of non-
reversion’ of a T-cell response, and significant interindividual
differences, is the limited utility of qualitative and quantitative
reversion of EC ELISPOT as a marker of treatment efficacy. It is
also clearly not a reliable predictor of treatment failure/adverse
outcomes. Furthermore, conversion to a positive test in a small
number of cases with negative results at the start of treatment was
also unrelated to the usual surrogates of disease severity (smear
grade, cavitatory radiologic disease) and not predictive of adverse
outcomes (clinical and bacteriologic).
Our study was conducted with an in-house ELISPOT test and
not the now commercially available versions. However, our in-
house test results are similar to results with the commercial test in
The Gamiba.[14,17,38,39,40] No mycobacterial cultures were
done for confirmation of sputum conversion at 2 months and to
declare a cured status after 6 months of therapy. Our TB cases
were treated in the government chest clinics according to national
TB guidelines. In addition, we did not have results from all cases at
all time points. However, about three-quarters of the study
population had samples taken at 3 or more timepoints.
Conclusions
We found TB treatment induces qualitative and quantitative
reversion of a positive IGRA in newly diagnosed cases of active TB
disease that occurs in a 2-step manner: there is a significant decline
within the first month of treatment and then on completion.
However, qualitative and quantitative reversion of a IGRA
ELISPOT has limited clinical utility as a surrogate marker of
treatment efficacy as it does not occur reliably in the majority of
cured individuals.
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